JP2010535242A5 - - Google Patents

Download PDF

Info

Publication number
JP2010535242A5
JP2010535242A5 JP2010520185A JP2010520185A JP2010535242A5 JP 2010535242 A5 JP2010535242 A5 JP 2010535242A5 JP 2010520185 A JP2010520185 A JP 2010520185A JP 2010520185 A JP2010520185 A JP 2010520185A JP 2010535242 A5 JP2010535242 A5 JP 2010535242A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
disorder
tcg
disease
aacg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010520185A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010535242A (ja
JP5563455B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/071738 external-priority patent/WO2009018431A2/en
Publication of JP2010535242A publication Critical patent/JP2010535242A/ja
Publication of JP2010535242A5 publication Critical patent/JP2010535242A5/ja
Application granted granted Critical
Publication of JP5563455B2 publication Critical patent/JP5563455B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010520185A 2007-08-01 2008-07-31 Ｔｌｒ９の新規な合成アゴニスト Active JP5563455B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US95325107P 2007-08-01 2007-08-01
US60/953,251 2007-08-01
US98360107P 2007-10-30 2007-10-30
US60/983,601 2007-10-30
US98715107P 2007-11-12 2007-11-12
US60/987,151 2007-11-12
US1529207P 2007-12-20 2007-12-20
US61/015,292 2007-12-20
PCT/US2008/071738 WO2009018431A2 (en) 2007-08-01 2008-07-31 Novel synthetic agonists of tlr9

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014120860A Division JP5816720B2 (ja) 2007-08-01 2014-06-11 Ｔｌｒ９の新規な合成アゴニスト

Publications (3)

Publication Number Publication Date
JP2010535242A JP2010535242A (ja) 2010-11-18
JP2010535242A5 true JP2010535242A5 (cg-RX-API-DMAC10.html) 2013-05-02
JP5563455B2 JP5563455B2 (ja) 2014-07-30

Family

ID=40305273

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010520185A Active JP5563455B2 (ja) 2007-08-01 2008-07-31 Ｔｌｒ９の新規な合成アゴニスト
JP2014120860A Active JP5816720B2 (ja) 2007-08-01 2014-06-11 Ｔｌｒ９の新規な合成アゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014120860A Active JP5816720B2 (ja) 2007-08-01 2014-06-11 Ｔｌｒ９の新規な合成アゴニスト

Country Status (12)

Country Link
US (2) US7960362B2 (cg-RX-API-DMAC10.html)
EP (3) EP2650369B1 (cg-RX-API-DMAC10.html)
JP (2) JP5563455B2 (cg-RX-API-DMAC10.html)
KR (1) KR20100053598A (cg-RX-API-DMAC10.html)
CN (3) CN102864151B (cg-RX-API-DMAC10.html)
AU (1) AU2008282172B2 (cg-RX-API-DMAC10.html)
BR (1) BRPI0813981A2 (cg-RX-API-DMAC10.html)
CA (1) CA2693266C (cg-RX-API-DMAC10.html)
ES (2) ES2585239T3 (cg-RX-API-DMAC10.html)
IN (1) IN2010KN00195A (cg-RX-API-DMAC10.html)
RU (1) RU2468819C2 (cg-RX-API-DMAC10.html)
WO (1) WO2009018431A2 (cg-RX-API-DMAC10.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7276489B2 (en) * 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
US8158768B2 (en) * 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US7354907B2 (en) * 2003-02-07 2008-04-08 Idera Pharmaceuticals, Inc. Short immunomodulatory oligonucleotides
JP4874801B2 (ja) * 2003-06-11 2012-02-15 イデラ ファーマシューティカルズ インコーポレイテッド 安定化免疫調節オリゴヌクレオチド
MXPA06000619A (es) * 2003-07-15 2006-04-11 Hybridon Inc Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion.
JP4989225B2 (ja) * 2003-09-25 2012-08-01 コーリー ファーマシューティカル グループ，インコーポレイテッド 核酸親油性接合体
CA2693266C (en) * 2007-08-01 2015-06-30 Idera Pharmaceuticals, Inc. Novel synthetic agonists of tlr9
JP2012516352A (ja) * 2009-01-30 2012-07-19 イデラ ファーマシューティカルズ インコーポレイテッド Ｔｌｒ９の合成アゴニスト
KR101856462B1 (ko) 2009-03-25 2018-05-10 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 병원체에 대한 포유동물의 선천성 면역 저항성의 자극을 위한 조성물
US20120045433A1 (en) * 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
US8709419B2 (en) 2010-08-17 2014-04-29 Hoffmann-La Roche, Inc. Combination therapy
US9295669B2 (en) 2010-12-14 2016-03-29 Hoffman La-Roche Inc. Combination therapy for proliferative disorders
AU2014205544B2 (en) * 2013-01-08 2018-07-12 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
GB2514591A (en) * 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
AU2015269412B2 (en) 2014-06-04 2020-03-12 Exicure Operating Company Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
WO2016040956A1 (en) * 2014-09-12 2016-03-17 Vantage Specialty Chemicals, Inc. Derivatives of 1,3-propanediol
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
CA2964155A1 (en) * 2014-10-10 2016-04-14 Idera Pharmaceuticals, Inc. Treatment of cancer using tlr9 agonist with checkpoint inhibitors
WO2016081911A2 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
WO2017052403A1 (ru) * 2015-09-25 2017-03-30 Анатолий Викторович ЗАЗУЛЯ Изготовление таблетки с механизмом повышения терапевтической эффективности лекарственного средства нанодозой микрорнк
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
US10463686B2 (en) 2016-09-15 2019-11-05 Idera Pharmaceuticals, Inc. Immune modulation with TLR9 agonists for cancer treatment
CA3045944A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
WO2018112223A1 (en) 2016-12-14 2018-06-21 Progenity Inc. Treatment of a disease of the gastrointestinal tract with a tlr modulator
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
CN116813705A (zh) 2017-07-05 2023-09-29 凯惠科技发展(上海)有限公司 一种肽类化合物、其应用及含其的组合物
WO2019066571A2 (ko) 2017-09-28 2019-04-04 연세대학교 산학협력단 골수유래 면역반응 억제세포의 제조방법, 이에 의해 제조된 골수유래 면역반응 억제세포 및 그 용도
WO2021007160A1 (en) 2019-07-05 2021-01-14 Tambo, Inc. Trans-cyclooctene bioorthogonal agents and uses in cancer and immunotherapy
WO2021174024A1 (en) 2020-02-28 2021-09-02 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
EP4175640A1 (en) 2020-07-02 2023-05-10 VIIV Healthcare Company Method of achieving hiv viral remission using long-acting antiretroviral agents
JP2023537066A (ja) 2020-08-07 2023-08-30 タンボ・インコーポレイテッド トランス－シクロオクテン生体直交型薬剤並びに癌及び免疫療法における使用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030026782A1 (en) * 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
WO1998055609A1 (en) * 1997-06-06 1998-12-10 The Regents Of The University Of California Inhibitors of dna immunostimulatory sequence activity
US6562798B1 (en) * 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6673613B2 (en) * 2000-07-26 2004-01-06 Cognis Corporation Use of CYP52A2A promoter to increase gene expression in yeast
US6503734B1 (en) * 2000-07-26 2003-01-07 Cognis Corporation Cytochrome b5 gene and protein of Candida tropicalis and methods relating thereto
EP1364010B1 (en) * 2000-12-27 2010-06-16 Dynavax Technologies Corporation Immunomodulatory polynucleotides and methods of using the same
RU2194502C2 (ru) * 2000-12-27 2002-12-20 Наровлянский Александр Наумович Иммуномодулятор - метаболик - детоксикант - адаптоген - радиопротектор
KR100985457B1 (ko) * 2001-06-21 2010-10-06 다이나박스 테크놀로지 코퍼레이션 키메라 면역조절 화합물 및 그것들의 사용 방법
US7276489B2 (en) 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
DK1992635T3 (da) * 2002-12-23 2012-03-05 Dynavax Tech Corp Oligonukleotider med immunstimulatorisk sekvens og fremgangsmåder til anvendelse af disse
EP1620070A2 (en) * 2003-04-29 2006-02-01 Centocor, Inc. Toll-like receptor 9 effector agents and uses thereof
JP4874801B2 (ja) * 2003-06-11 2012-02-15 イデラ ファーマシューティカルズ インコーポレイテッド 安定化免疫調節オリゴヌクレオチド
US20050244410A1 (en) * 2004-04-29 2005-11-03 Ashlyn Bassiri Toll-like receptor 9 effector agents and uses thereof
BRPI0512110A (pt) * 2004-06-15 2007-10-23 Idera Pharmaceutical Inc multìmeros de oligonucleotìdeos imunoestimulatórios
ES2544877T3 (es) * 2005-10-12 2015-09-04 Idera Pharmaceuticals Compuestos oligonucleótidos inmuno reguladores (IRO) para modular la respuesta inmune basada en receptor semejante a Toll
EP1942945B1 (en) * 2005-11-07 2011-10-19 Idera Pharmaceuticals Immunostimulatory properties of oligonucleotide-based compounds comprising modified immunostimulatory dinucleotides
EP1962909A4 (en) * 2005-12-20 2012-04-18 Idera Pharmaceuticals Inc IMMUNOSTIMULATING ACTIVITY OF PALINDROMIC IMMUNOMODULATORY OLIGONUCLEOTIDES (IMO TM) CONTAINING DIFFERENT LENGTHS OF PALINDROMIC SEGMENTS
EP2079305A4 (en) * 2006-12-12 2010-01-27 Idera Pharmaceuticals Inc SYNTHETIC AGONISTS OF TLR9
WO2008131074A1 (en) * 2007-04-19 2008-10-30 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders
CA2693266C (en) * 2007-08-01 2015-06-30 Idera Pharmaceuticals, Inc. Novel synthetic agonists of tlr9

Similar Documents

Publication Publication Date Title
JP7213566B2 (ja) 病原体ワクチンならびにその製造および使用方法
JP2013507905A5 (cg-RX-API-DMAC10.html)
RU2010107207A (ru) Новые синтетические агонисты tlr9
CN1604795B (zh) 具有提高的活性的组合基序免疫刺激寡肽
JP6697384B2 (ja) 予防的および治療的使用のための免疫刺激剤としての球状の核酸ベース構築物
JP2010532996A5 (cg-RX-API-DMAC10.html)
US11060096B2 (en) RNA-based compositions and adjuvants for prophylactic and therapeutic treatment
CA2570786C (en) Modified cpg-containing oligonucleotide multimers in immune stimulation
AU2006304205C1 (en) Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
JP2008501807A5 (cg-RX-API-DMAC10.html)
JP5455629B2 (ja) 増強された免疫刺激活性を有する疎水性Ｔ類似体を含有するＣｐＧオリゴヌクレオチド類似体
CA2752694A1 (en) Synthetic rna-based agonists of tlr7
JP2010512421A5 (cg-RX-API-DMAC10.html)
US20160194642A1 (en) Spherical nucleic acid-based constructs as immunoregulatory agents
US12473553B2 (en) RNA nanostructures and methods of making and using RNA nanostructures
ES2486298T3 (es) Análogos de oligonucleótidos inmunoestimuladores que contienen azúcares modificados
HRP20150566T1 (hr) Kompozicija za inhibiciju ekspresije gena i njegova upotreba
JP2010507386A (ja) オリゴリボヌクレオチドおよびその使用
JP2010504982A (ja) Ｔｌｒのリガンドと抗ウイルス剤との組成物
CN101160401A (zh) 免疫刺激寡核苷酸
WO2005083076A1 (ja) インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
CN103596594A (zh) 自身凝胶化核酸
WO2017007027A1 (ja) 免疫刺激オリゴヌクレオチド複合体
JP2023527525A (ja) インターフェロン誘導オリゴヌクレオチド二重鎖および使用方法
JP5930146B2 (ja) 免疫刺激オリゴヌクレオチドおよび前記免疫刺激オリゴヌクレオチドを含む治療剤